Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mestex AG
Bayer Sells Nebido To Grünenthal Amid Shift In Focus To Cell And Gene Pipeline
The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.
- Other Names / Subsidiaries
- Grünenthal GmbH
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.